JPH0249712A - Cosmetic - Google Patents
CosmeticInfo
- Publication number
- JPH0249712A JPH0249712A JP19978388A JP19978388A JPH0249712A JP H0249712 A JPH0249712 A JP H0249712A JP 19978388 A JP19978388 A JP 19978388A JP 19978388 A JP19978388 A JP 19978388A JP H0249712 A JPH0249712 A JP H0249712A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- dandruff
- oxide
- antiseborrheic
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 22
- 208000001840 Dandruff Diseases 0.000 claims abstract description 18
- 150000001412 amines Chemical class 0.000 claims abstract description 12
- 230000002087 whitening effect Effects 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 14
- 235000010323 ascorbic acid Nutrition 0.000 abstract description 7
- 239000011668 ascorbic acid Substances 0.000 abstract description 7
- 229960005070 ascorbic acid Drugs 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 2
- 230000009471 action Effects 0.000 abstract description 2
- 229910052717 sulfur Inorganic materials 0.000 abstract description 2
- 239000011593 sulfur Substances 0.000 abstract description 2
- 229940043810 zinc pyrithione Drugs 0.000 abstract description 2
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- -1 dimethyloleylamine oxide Chemical compound 0.000 description 9
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000000440 bentonite Substances 0.000 description 4
- 229910000278 bentonite Inorganic materials 0.000 description 4
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 4
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 4
- 239000002734 clay mineral Substances 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 229940057995 liquid paraffin Drugs 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 4
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 4
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 4
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229940042585 tocopherol acetate Drugs 0.000 description 4
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 3
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 3
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 3
- 244000061508 Eriobotrya japonica Species 0.000 description 3
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 3
- 241000234435 Lilium Species 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000010495 camellia oil Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- UCTLRSWJYQTBFZ-DDPQNLDTSA-N cholesta-5,7-dien-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC=C21 UCTLRSWJYQTBFZ-DDPQNLDTSA-N 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- 229960004705 kojic acid Drugs 0.000 description 3
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- UTTVXKGNTWZECK-UHFFFAOYSA-N n,n-dimethyloctadecan-1-amine oxide Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)[O-] UTTVXKGNTWZECK-UHFFFAOYSA-N 0.000 description 3
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 3
- 229940081510 piroctone olamine Drugs 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 239000011787 zinc oxide Substances 0.000 description 3
- 235000014692 zinc oxide Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- QCTZUSWOKFCWNB-QXMHVHEDSA-N (z)-n,n-dimethyloctadec-9-en-1-amine oxide Chemical compound CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)[O-] QCTZUSWOKFCWNB-QXMHVHEDSA-N 0.000 description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 229940105847 calamine Drugs 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940031578 diisopropyl adipate Drugs 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 229910052864 hemimorphite Inorganic materials 0.000 description 2
- 235000020721 horse chestnut extract Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229960001325 triclocarban Drugs 0.000 description 2
- 229940045136 urea Drugs 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 229930007845 β-thujaplicin Natural products 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NZGKLLOWEPXNDG-SSCMEWPNSA-N (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-2,4a,6a,6b,9,9,12a-heptamethyl-10-octadecanoyloxy-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1(C)C NZGKLLOWEPXNDG-SSCMEWPNSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 229930007886 (R)-camphor Natural products 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- LLKXPXLHGVJRIP-UHFFFAOYSA-N 22-methyltricosyl(oxido)azanium Chemical compound CC(C)CCCCCCCCCCCCCCCCCCCCC[NH2+][O-] LLKXPXLHGVJRIP-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 244000280244 Luffa acutangula Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 241000596467 Ononis Species 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241001647091 Saxifraga granulata Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- HWDGVJUIHRPKFR-UHFFFAOYSA-I copper;trisodium;18-(2-carboxylatoethyl)-20-(carboxylatomethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18-dihydroporphyrin-21,23-diide-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Cu+2].N1=C(C(CC([O-])=O)=C2C(C(C)C(C=C3C(=C(C=C)C(=C4)[N-]3)C)=N2)CCC([O-])=O)C(=C([O-])[O-])C(C)=C1C=C1C(CC)=C(C)C4=N1 HWDGVJUIHRPKFR-UHFFFAOYSA-I 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002910 effect on acne Effects 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- GORUZQZCUPHPAX-UHFFFAOYSA-N n,n-dimethyldocosan-1-amine oxide Chemical compound CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)[O-] GORUZQZCUPHPAX-UHFFFAOYSA-N 0.000 description 1
- IBOBFGGLRNWLIL-UHFFFAOYSA-N n,n-dimethylhexadecan-1-amine oxide Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)[O-] IBOBFGGLRNWLIL-UHFFFAOYSA-N 0.000 description 1
- SFBHPFQSSDCYSL-UHFFFAOYSA-N n,n-dimethyltetradecan-1-amine Chemical compound CCCCCCCCCCCCCCN(C)C SFBHPFQSSDCYSL-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- BJLVKAGPBSJBSJ-UHFFFAOYSA-N n-dodecyl-n-methyldodecan-1-amine oxide Chemical compound CCCCCCCCCCCC[N+](C)([O-])CCCCCCCCCCCC BJLVKAGPBSJBSJ-UHFFFAOYSA-N 0.000 description 1
- WWRMRGSSMGHJPF-UHFFFAOYSA-N n-dodecyl-n-methylhydroxylamine Chemical compound CCCCCCCCCCCCN(C)O WWRMRGSSMGHJPF-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 229940079841 sodium copper chlorophyllin Drugs 0.000 description 1
- 235000013758 sodium copper chlorophyllin Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000009538 yokuinin Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は、薬剤のもつ効果を十分発揮させた化粧料に関
する。更に詳しくは、アミンオキシドの一種又は二種以
上と、美白剤、フケ防止剤及び抗脂漏剤からなる群から
選ばれる一種又は二種以上とを含有することを特徴とす
る化粧料に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to cosmetics that fully exhibit the effects of drugs. More specifically, the present invention relates to a cosmetic containing one or more amine oxides and one or more selected from the group consisting of whitening agents, anti-dandruff agents, and antiseborrheic agents.
[従来の技術]
皮膚の表面ば皮膚角質層と呼ばれ、本来、体外からの異
物の侵入を防御するバリヤーとしての生理的機能を有す
るものであるため、ただ単に従来化粧料に常用されてき
た基剤中に薬効成分を配合しただけでは、充分な薬剤の
効果が得られない。[Prior art] The surface of the skin is called the stratum corneum, and it originally has a physiological function as a barrier to prevent foreign substances from entering the body, so it has been commonly used in cosmetics. Merely incorporating medicinal ingredients into a base does not provide sufficient drug effects.
U発明が解決しようとする課題]
本発明者等は上記問題点に鑑み、薬効成分の持つ効果を
充分発揮される化粧料を開発すべく鋭意研究した結果、
本発明を完成するに至った。Problems to be Solved by the Invention] In view of the above-mentioned problems, the present inventors conducted intensive research to develop cosmetics that fully demonstrate the effects of medicinal ingredients.
The present invention has now been completed.
[課題を解決するための手段]
すなわち本発明は、アミンオキシドの一種又は二種以上
と、美白剤、フケ防止剤及び抗脂漏剤からなる群から選
ばれる一種又は二種以上とを含有することを特徴とする
化粧料である。[Means for Solving the Problems] That is, the present invention contains one or more amine oxides and one or more selected from the group consisting of whitening agents, antidandruff agents, and antiseborrheic agents. It is a cosmetic product that is characterized by:
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.
本発明で用いられるアミンオキシドとしては、下記一般
式(A)〜(C)のものが挙げられる。Examples of the amine oxide used in the present invention include those of the following general formulas (A) to (C).
R2−N→0
(A)
(式中R1、R2およびR3は炭素原子数1から24の
直鎖または分枝の飽和又は不飽和の炭化水素基を表わし
、R1、R2、R3のうち少なくとも1個は炭素原子数
8以上の直鎖または分枝の飽和又は不飽和の炭化水素基
を表わす。)
一般式(A)で表わされるアミンオキシドの具体例とし
ては、ジメチルラウリルアミンオキシド、ジメチルミリ
スチルアミンオキシド、ジメチルセチルアミンオキシド
、ジメチルステフリルアミンオキシド、ジメチルオレイ
ルアミンオキシド、ジメチルベヘニルアミンオキシド、
メチルジラウリルアミンオキシドなどが挙げられる。R2-N→0 (A) (wherein R1, R2, and R3 represent a straight chain or branched saturated or unsaturated hydrocarbon group having 1 to 24 carbon atoms, and at least one of R1, R2, and R3 represents a straight chain or branched saturated or unsaturated hydrocarbon group having 8 or more carbon atoms.) Specific examples of the amine oxide represented by the general formula (A) include dimethyl lauryl amine oxide, dimethyl myristyl amine oxide, dimethylcetylamine oxide, dimethylstefurylamine oxide, dimethyloleylamine oxide, dimethylbehenylamine oxide,
Examples include methyl dilaurylamine oxide.
CH2CR20H
R4−N→0
(B)
枝の飽和又は不飽和の炭化水素基を表わす。) R3
R5(OCH2CH12)n N→0 (C)H
3
(式中R5は炭素原子IJI18から24の直鎮または
分校の飽和又は不飽和の炭化・水素基を表わし、nは1
から5の整数を表わす。)
本発明においては、これらアミンオキシドの一種または
二柾以上が任意に選択され、用いられる。CH2CR20H R4-N→0 (B) Represents a branched saturated or unsaturated hydrocarbon group. ) R3 R5(OCH2CH12)n N→0 (C)H
3 (wherein R5 represents a straight or branched saturated or unsaturated hydrocarbon/hydrogen group of carbon atoms IJI18 to 24, and n is 1
represents an integer from 5 to 5. ) In the present invention, one or more of these amine oxides are arbitrarily selected and used.
本発明に用いられる美白剤としては、アスコルビン酸、
シバルミチン酸アスコルビル、アスコルビン酸2−硫酸
、ユキノシタ抽出物、プラセンタ抽出物、コウジ酸等が
挙げられる。As the whitening agent used in the present invention, ascorbic acid,
Examples include ascorbyl civalmitate, ascorbic acid 2-sulfuric acid, saxifrage extract, placenta extract, kojic acid, and the like.
本発明に用いられるフケ防止剤としては、ジンクピリチ
オン、トリクロロカルバニリド、ピロクトンオラミン等
が挙げられる。Anti-dandruff agents used in the present invention include zinc pyrithione, trichlorocarbanilide, piroctone olamine, and the like.
本発明に用いられる抗脂漏剤としては、イオウ、シャク
ヤク、ボタンピ、塩酸ピリドキシン、トリバルミチン酸
ピリドキシン、オトギリソウ等が挙げられる。Examples of the antiseborrheic agent used in the present invention include sulfur, peony, botanical, pyridoxine hydrochloride, pyridoxine tribalmitate, Hypericum perforatum, and the like.
本発明で用いられる美白剤、フケ防止剤及び抗脂漏剤は
、本発明の界面活性剤と混合して用いて皮膚に塗布する
ことにより、薬剤の持つ効果が充分発揮される。局所作
用を目的とする薬効成分ならびに全身作用を目的とする
薬効成分とも同様に優れた効果を発揮する。When the whitening agent, anti-dandruff agent, and anti-seborrheic agent used in the present invention are mixed with the surfactant of the present invention and applied to the skin, the effects of the agents are fully exhibited. Both medicinal ingredients intended for local action and medicinal ingredients intended for systemic action exhibit excellent effects.
本発明で用いられる美白剤、フケ防止剤及び抗脂漏剤の
配合量は、所望の薬効を奏するに充分な量であればよく
、それは薬効成分の種類、使用者の肌質、症状等によっ
て異なるものであり、−概にはいえないが、概ね薬効成
分1重量%に対して、アミンオキシド0.001〜50
重量%である。The amount of the whitening agent, anti-dandruff agent, and anti-seborrheic agent used in the present invention may be sufficient as long as it has the desired medicinal effect, and it depends on the type of medicinal ingredient, the skin type and symptoms of the user, etc. -Although it cannot be said generally, approximately 0.001 to 50 amine oxide per 1% by weight of the medicinal ingredient.
Weight%.
上記のアミンオキシドは、薬効成分を適宜混合してその
まま用いてもよいが、使用感触や適用のしゃすぎ等を勘
案して、−船釣には構成成分を適当な化粧料中、例えば
クリーム、ゲル、ローラ3ン、乳)改等の基剤中に混合
して用いられる。The above-mentioned amine oxide may be used as it is after suitably mixing the medicinal ingredients, but taking into consideration the feel of use and the ease of application, for boat fishing, the constituent ingredients may be mixed into an appropriate cosmetic, such as a cream, etc. It is used by mixing it into a base such as gel, roller 3 run, milk), etc.
その場合の各々の構成成分の配合量は、同じく薬効成分
の種類等によって異なるが、概ね以下の範囲が好ましい
配合量範囲である。すなわち、アミンオキシドの配合量
は化粧料中0.001〜10重量%が好ましく、より好
ましくは0.01〜5重量%であり、薬効成分は0.0
01〜10重量%が好ましく、より好ましくはo、oi
〜5重量%である。In that case, the amount of each component to be blended will vary depending on the type of medicinal ingredient, etc., but the following range is generally the preferred range of the amount to be blended. That is, the amount of amine oxide blended in the cosmetic is preferably 0.001 to 10% by weight, more preferably 0.01 to 5% by weight, and the medicinal ingredient is 0.0% by weight.
01 to 10% by weight is preferable, more preferably o, oi
~5% by weight.
本発明に係る化粧(−1中には、上記の必須構成成分の
他に一般的に化粧料等に配合される成分を配合すること
ができる。それらの成分としては、コウホネ、オウバク
抽出物、オウゴン抽出物、アイビー抽出物、セイヨウノ
コギリソウ抽出物、センブリ抽出物、シラカバ抽出物、
マロニエ抽出物、ビワ抽出物、グリチルリチン酸、β−
グリチルレヂン酸、グリチルリチン酸モノアンモニウム
、グリデルレチン酸ステアリル、ヒノキチオール、Dカ
ンフル、L−メントール、酸化亜鉛、カラミン、アラン
トイン、塩酸ジフェンヒドラミン等の消炎剤、ニンジン
抽出物、ゼニアオイ抽出物、ニンニク抽出物、アイリス
抽出物、ヨクイニン抽出物、ブドウ抽出物、ヘチマ抽出
物、モモ抽出物、酵母抽出物、ローヤルゼリー、銅クロ
ロフイリンナトリウム、γ−オリザノール、ヒノキチオ
ール、β−カロチン、尿素、アラントイン、カラギーナ
ン、エチニルエストラジオール、L−アラニン、DL−
セリン、アデノシン三リン酸二ナトリウム、パントテニ
ルエチルエーテル、ビオチン、イノジット、エルゴカル
シフェロール、ニコチン酸アミド等の賦活剤、クロバナ
ヒキオコシ、7−オリザノール、DL−カンフル、テ゛
キストラン硫酸ナトリウム、リルイン酸DL−α−トコ
フェロール、酢酸DL−α−トコフェロール等の血行促
進剤、レゾルシン、乳酸等の角質軟化剤、スギナ抽出物
、クワ、コウホネ、オドリコソウ抽出物、マロニエ抽出
物、ブドウリース抽出物、ヨモギ抽出物、酸化佃鉛、カ
ラミン等の収斂剤、アロエ抽出物、ユリ抽出物、クイン
スシード、キサンタンガム、デキストラン硫酸ナトリウ
ム、コンドロイチン硫酸ナトリウム、カラギーナン、ヒ
アルロン酸ナトリウム、ウロカニン酸等の保湿剤、オリ
ブ油、ローヤルゼリーカキ抽出物、酵母抽出物、アスコ
ルビン酸、イノジット等の栄養剤、アボカド油、サフラ
ワー油、茶実油、ホホバ油、オノニス抽出物、尿素、リ
ノール酸、コレステロール、デヒドロコレステロール、
ジヒドロコレステロール、ラノステロール、ステアリン
酸グリチルレチニル等の柔軟剤、多価アルコール、油分
、ワックス、酸、アルカリ、その他の界面活性剤、粉末
、顔料、染料、防腐間ばい剤、酸化防止剤、紫外線吸収
剤、キレート剤、水溶性高分子、モンモリロナイト、ア
ルコール、溶媒、香料等が挙げられる。In addition to the above-mentioned essential components, the cosmetics (-1) according to the present invention can contain ingredients that are generally included in cosmetics. Scutellaria scutellariae extract, ivy extract, yarrow extract, Japanese cabbage extract, birch extract,
Horse chestnut extract, loquat extract, glycyrrhizic acid, β-
Anti-inflammatory agents such as glycyrrhizic acid, monoammonium glycyrrhizinate, stearyl glyderretinate, hinokitiol, D-camphor, L-menthol, zinc oxide, calamine, allantoin, diphenhydramine hydrochloride, carrot extract, mallow extract, garlic extract, iris extract , Yokuinin extract, grape extract, loofah extract, peach extract, yeast extract, royal jelly, sodium copper chlorophyllin, γ-oryzanol, hinokitiol, β-carotene, urea, allantoin, carrageenan, ethinylestradiol, L-alanine ,DL-
Activators such as serine, disodium adenosine triphosphate, pantothenyl ethyl ether, biotin, inosit, ergocalciferol, nicotinamide, black snail, 7-oryzanol, DL-camphor, sodium textran sulfate, DL-α-riluic acid Blood circulation promoters such as tocopherol and DL-α-tocopherol acetate, keratin softeners such as resorcin and lactic acid, horsetail extract, mulberry, mulberry root, deadlock root extract, horse chestnut extract, grape wreath extract, mugwort extract, oxidized tsukuda Astringents such as lead and calamine, aloe extract, lily extract, quince seed, xanthan gum, sodium dextran sulfate, sodium chondroitin sulfate, carrageenan, sodium hyaluronate, moisturizing agents such as urocanic acid, olive oil, royal jelly oyster extract, Yeast extract, ascorbic acid, nutritional supplements such as Inojit, avocado oil, safflower oil, tea seed oil, jojoba oil, ononis extract, urea, linoleic acid, cholesterol, dehydrocholesterol,
Softeners such as dihydrocholesterol, lanosterol, glycyrrhetinyl stearate, polyhydric alcohols, oils, waxes, acids, alkalis, other surfactants, powders, pigments, dyes, preservatives, antioxidants, ultraviolet absorbers, Examples include chelating agents, water-soluble polymers, montmorillonite, alcohols, solvents, fragrances, and the like.
[実施例]
つぎに実施例を挙げて本発明を具体的に説明するが、本
発明はこれら実施例にのみ限定されるものではない。配
合量は重量%である。[Examples] Next, the present invention will be specifically explained with reference to Examples, but the present invention is not limited only to these Examples. The blending amount is in weight%.
実施例1 クリーム
(1アスコルビン酸2−硫酸
(2プロピレングリコール
(3グリセリン
(4流動パラフィン
(5アジピン酸ジイソプロピル
(6ステアリルジメチル
アミンオキシド
(7) グリセリンモノ
脂肪酸エステル
(8) 防腐剤
1.0
8.0
5.0
1.0
3.0
0.8
1.5
適量
(9) 粘土鉱物(ベントナイト)6.0(10)
精製水 残余比較例1 クリーム
(1アスコルビン酸2−硫酸 1.0(2プロピレン
グリコール 8.0(3グリセリン
5.0(4流動パラフィン 1,0(5ア
ジピン酸ジイソプロピル 3.0(6グリセリンモノ
脂肪酸エステル 1.5
(7) 防腐剤 適量(8)
粘土鉱物(ベントナイト)6.0(9) 精製水
残余実施例1及び比較例1で調整しrニ
クリームについて、美白効果を比較した。試験方法及び
評価方法を以下に示す。Example 1 Cream (1) Ascorbic acid 2-sulfuric acid (2) Propylene glycol (3) Glycerin (4) Liquid paraffin (5) Diisopropyl adipate (6) Stearyl dimethylamine oxide (7) Glycerin monofatty acid ester (8) Preservative 1.0 8. 0 5.0 1.0 3.0 0.8 1.5 Adequate amount (9) Clay mineral (bentonite) 6.0 (10)
Purified water Remaining comparative example 1 Cream (1 Ascorbic acid 2-sulfuric acid 1.0 (2 Propylene glycol 8.0 (3 Glycerin)
5.0 (4 Liquid paraffin 1,0 (5 Diisopropyl adipate 3.0 (6 Glycerin monofatty acid ester 1.5 (7) Preservative appropriate amount (8)
Clay mineral (bentonite) 6.0 (9) Purified water
The skin whitening effects of the remaining rnicreams prepared in Example 1 and Comparative Example 1 were compared. The test method and evaluation method are shown below.
すなわち、肝斑患者女子各20名の顔部に、実施例1及
び比較例1で調整したクリームを4週間連用し、その前
後において判定した。That is, the creams prepared in Example 1 and Comparative Example 1 were continuously applied to the faces of 20 female melasma patients for 4 weeks, and evaluations were made before and after that.
判定基準は、
「肝斑の著明な改善効果」 (スコア2)「明らかな改
善効果」 (スコア1)
「微弱な改善効果」 (スコア0.5)「変化なし」
(スコアO)
として各基剤側に平均スコアを求めた。The criteria for evaluation are: ``significant improvement effect on melasma'' (score 2) ``obvious improvement effect'' (score 1) ``slight improvement effect'' (score 0.5) ``no change''
(Score O) An average score was determined for each base side.
表−1より明らかな様に実施例1のクリームが美白作用
に優れていることがわかる。As is clear from Table 1, it can be seen that the cream of Example 1 has excellent whitening effect.
実施例2 クリーム
(1) コウジ酸
(2) デヒドロコレステロール
(3) 茶実油
2.0
0.5
0.2
(4) グリセリンモノ
脂肪酸エステル
(5) ラウリルジヒドロキジ
エチルアミンオキシド
(6) 流動パラフィン
7) セタノール
8) 防腐剤
9) 粘土鉱物(ベントナイト)
10) 香料
11) イオン交換水
1.4
1.2
4.0
1.0
適量
5.0
適量
残余
(8) 粘土鉱物(ベントナイト)
(9) 香料
(10) イオン交換水
5.0
適量
残余
実施例2、比較例2の美白効果も同様な方法で試験した
。結果を表−2に示した。Example 2 Cream (1) Kojic acid (2) Dehydrocholesterol (3) Tea seed oil 2.0 0.5 0.2 (4) Glycerin monofatty acid ester (5) Lauryldihydroxydiethylamine oxide (6) Liquid paraffin 7 ) Setanol 8) Preservative 9) Clay mineral (bentonite) 10) Fragrance 11) Ion exchange water 1.4 1.2 4.0 1.0 Appropriate amount 5.0 Appropriate amount remainder (8) Clay mineral (bentonite) (9) Fragrance (10) Ion-exchanged water 5.0 Appropriate amount Remaining Example 2 and Comparative Example 2 were tested for whitening effect in the same manner. The results are shown in Table-2.
比較例3 クリーム
(1) コウジ酸
(2) デヒドロコレステロール
(3) 茶実油
(4) グリセリンモノ
脂肪酸エステル
(5) 流動パラフィン
(6) セタノール
(7) 防腐剤
2.0
0.5
0.2
1.4
4.0
1.0
適量
表−2より明らかな様に実施例2のクリームが美白作用
に優れていることがわかる。また皮膚柔軟性においても
優れた効果を示した。Comparative Example 3 Cream (1) Kojic acid (2) Dehydrocholesterol (3) Tea seed oil (4) Glycerin monofatty acid ester (5) Liquid paraffin (6) Setanol (7) Preservative 2.0 0.5 0.2 1.4 4.0 1.0 Appropriate Amount As is clear from Table 2, it can be seen that the cream of Example 2 has excellent whitening effect. It also showed excellent effects on skin flexibility.
実施例3 ヘアトニック
(1) ピロクトンオラミン
(2) 酢酸DL−α−トコフェロール(3)ユリ抽
出物
1.0
0.3
0.05
(4) 塩酸ピリドキシン 0.07
(5) ヒノキチール 0.03
(6) オレイルジメチル
アミンオキシド 0.7
(7) ポリオキシエチレン(40モル付加)硬化ヒ
マシ油誘導体 0.5
(8) エチルアルコール 50.0(
9)緩衝剤 適量(10)香料
適量(11)精製水
残余比較例3 ヘアトニック
(1ピロクトンオラミン 1.0(2酢酸
DL−α−トコフェロール 0.3(3ユリ抽出物
0.05(4塩酸ピリドキシン
0.07(5ヒノキチール
0,03(6ポリオキシエチレン(40モル付加
)硬化ヒマシ油誘導体 0.5
(7) エチルアルコール 50.0(
8) 緩(÷i剤
(9) 香料
(10)精製水
適量
適量
残余
実施例3、比較例3のふけ抑制試験を行なった。Example 3 Hair tonic (1) Piroctone olamine (2) DL-α-tocopherol acetate (3) Lily extract 1.0 0.3 0.05 (4) Pyridoxine hydrochloride 0.07
(5) Hinoki teal 0.03
(6) Oleyl dimethylamine oxide 0.7 (7) Polyoxyethylene (40 mol addition) hydrogenated castor oil derivative 0.5 (8) Ethyl alcohol 50.0 (
9) Buffering agent appropriate amount (10) Flavoring agent appropriate amount (11) Purified water
Residue Comparative Example 3 Hair tonic (1 Piroctone olamine 1.0 (2 Acetate DL-α-tocopherol 0.3 (3 Lily extract)
0.05 (pyridoxine 4-hydrochloride
0.07 (5 hinokitiru
0.03 (6 polyoxyethylene (40 mol addition) hydrogenated castor oil derivative 0.5 (7) Ethyl alcohol 50.0 (
8) Mild (÷i agent (9) Fragrance (10) Appropriate amount of purified water Appropriate amount of remainder A dandruff suppression test was conducted for Example 3 and Comparative Example 3.
試験方法及び評価方法を以下に示す。The test method and evaluation method are shown below.
対象者として22〜36歳で、ふけの比較的多い男性を
12名選び、各試料につき、6名ずつ合計12名につい
てテストを行なった。試験開始前に普通のシャンプーで
洗髪し、洗髪後3日間に累積しふけを採取し、採取した
ふけの重量と、1力月間、上記実施例3及び比較例3で
調製したヘアトニックを使用し、試験期間終了時の最後
の洗髪後3日間に累積したふけの重量とを比較した。累
積したふけの採取は濾布つき吸引装置を用いて頭部を吸
引することにより行なった。Twelve men between the ages of 22 and 36 with relatively heavy dandruff were selected as subjects, and each sample was tested on six men for a total of twelve men. Before the start of the test, the hair was washed with a normal shampoo, the accumulated dandruff was collected for 3 days after the hair washing, and the weight of the collected dandruff was calculated using the hair tonic prepared in Example 3 and Comparative Example 3 for one month. The weight of dandruff accumulated during the three days after the last hair wash at the end of the test period was compared. Accumulated dandruff was collected by suctioning the head using a suction device with a filter cloth.
ヘアトニック使用によるふけの減少は以下の式で算出し
た。The reduction in dandruff due to the use of hair tonic was calculated using the following formula.
結果を表−3に示した。The results are shown in Table-3.
表−3より明らかな様に実施例3のヘアトニックがふけ
抑制効果に優れていることかわかる。As is clear from Table 3, the hair tonic of Example 3 has an excellent dandruff suppressing effect.
実施例4 乳液
(1塩酸ピリドキシン
(2サリチル酸
(3ビワ抽出物
(4’ L−メントール
(5セタノール
(6ワセリンP
(7スクワラン
(8ジメチルポリシロキサン
(9ポリオキシエチレン
(3モル付加)ステアリル
ジメチルアミンオキシド
10 グリセリンモノステアレート
11 グリセリン
12)ジプロピ1/ングリコール
】3 カルボキシビニルポリマー
4KOH
0,05
0,1
0,02
0,2
1,0
2,0
4,0
2,0
1,2
2,0
5,0
4,0
0,3
0,1
(15)防腐剤
(16)香料
(17)イオン交換水
比較例4 乳液
(1塩酸ピリドキシン
(2サリチル酸
(3ビワ抽出物
(4L、−メントール
(5) セタノール
(6ワセリンP
(7スクワラン
(8ジメチルポリシロキサン
(9グリセリンモノステアレート
(10グリセリン
(11ジブaピレングリコール
(12カルボキシビニルポリマー
(13KOH
(14防腐剤
(15香[↓
適量
適量
残余
0.05
0.1
0.02
0.2
1.0
2.0
4.0
2.0
2.0
5.0
4.0
0.3
0.1
適量
i!i量
(16)イオン交換水
残余
実施例4及び比較例4で調整した乳液について、アクネ
改善効果を比較した。試験方法及び評価方法については
、以下に示す。Example 4 Emulsion (1 pyridoxine hydrochloride (2 salicylic acid) 3 loquat extract (4' L-menthol (5 cetanol (6 vaseline P Oxide 10 Glycerin monostearate 11 Glycerin 12) Dipropy 1/N glycol 3 Carboxyvinyl polymer 4KOH 0,05 0,1 0,02 0,2 1,0 2,0 4,0 2,0 1,2 2, 0 5,0 4,0 0,3 0,1 (15) Preservative (16) Fragrance (17) Ion exchange water Comparative example 4 Emulsion (1 Pyridoxine hydrochloride (2 Salicylic acid (3) Loquat extract (4L, -Menthol ( 5) Setanol (6 Vaseline P (7 Squalane (8 Dimethylpolysiloxane) .05 0.1 0.02 0.2 1.0 2.0 4.0 2.0 2.0 5.0 4.0 0.3 0.1 Appropriate amount i!i amount (16) Remaining ion exchange water The acne-improving effects of the emulsions prepared in Example 4 and Comparative Example 4 were compared.The test method and evaluation method are shown below.
すなわち、にきびに悩む健康な女性20名の顔部に、実
施例4及び比較例4で調整した乳液を4週間連用し、そ
の前後において判定した。That is, the emulsions prepared in Example 4 and Comparative Example 4 were continuously applied to the faces of 20 healthy women suffering from acne for 4 weeks, and evaluations were made before and after.
判定基準は、
「アクネの著明な改善効果」 (スコア2)「明らかな
改善効果」 (スコア1)
「微弱な改善効果」 (スコア0.5)「変化なし」
(スコアO)
として各基剤別に平均スコアを求めた。結果を表−4に
示した。The judgment criteria are: ``Remarkable improvement effect on acne'' (Score 2) ``Clear improvement effect'' (Score 1) ``Weak improvement effect'' (Score 0.5) ``No change''
(Score O) An average score was determined for each base. The results are shown in Table-4.
表−4
本実施例5のヘアリキッドは、すぐれたふけ抑制効果を
示した。Table 4 The hair liquid of Example 5 showed an excellent dandruff suppressing effect.
表−4より明らかな様に実施例4の乳液がアクネ改善効
果に優れている事がわかる。As is clear from Table 4, it can be seen that the emulsion of Example 4 has an excellent acne-improving effect.
実施例5 ヘアリキッド
(1)トリクロロカルバニリド
(2) 酢酸DL−α−トコフェロール(3) ポ
リオキシプロピレン
(40モル付加)ブチルエーテル
(4エチルアルコール
(5オレイルジメチルアミンオキシド
(6ステアリルジメチルアミンオキシド(7香料
(8イオン交換水
0.3
0.1
15.0
50.0
1.2
0.4
適量
残余
実施例6 化粧水
■)アスコルビン酸2−硫酸
2 ブラセンタ抽出物
3 パントテニルエチルエーテル
4 ジラウリルメチルアミンオキシド
5 ベヘニルジメチルアミンオキシド
(6グリセリン
(71,3−ブチレングリコール
(8エチルアルコール
(9防腐剤
(10)緩衝剤
(11)イオン交換水
0.3
0.2
0.2
0.2
0.4
2.0
1.0
10.0
適量
適量
残余
本実施例6の化粧水は、すぐれた美白作用を示し、かつ
皮膚賦活作用も示した。Example 5 Hair liquid (1) Trichlorocarbanilide (2) DL-α-tocopherol acetate (3) Polyoxypropylene (40 mol addition) Butyl ether (4 Ethyl alcohol (5) Oleyl dimethylamine oxide (6) Stearyl dimethylamine oxide ( 7 Fragrance (8 Ion-exchanged water 0.3 0.1 15.0 50.0 1.2 0.4 Appropriate amount remaining Example 6 Lotion ■) Ascorbic acid 2-sulfuric acid 2 Placenta extract 3 Pantothenyl ethyl ether 4 Di Lauryl methylamine oxide 5 Behenyldimethylamine oxide (6 Glycerin (71,3-butylene glycol) 8 Ethyl alcohol (9 Preservative (10) Buffer (11) Ion exchange water 0.3 0.2 0.2 0.2 0.4 2.0 1.0 10.0 Appropriate amount Appropriate amount Residual The lotion of Example 6 exhibited an excellent whitening effect and also exhibited a skin revitalizing effect.
[発明の効果]
本発明に係る化粧料は、薬効成分の持つ効果を充分発揮
きせ、かつ安全性、使用感触も良好な化粧料である。[Effects of the Invention] The cosmetic according to the present invention is a cosmetic that fully exhibits the effects of medicinal ingredients, and is safe and feels good when used.
Claims (1)
フケ防止剤及び抗脂漏剤からなる群から選ばれる一種又
は二種以上とを含有することを特徴とする化粧料。(1) one or more amine oxides and a whitening agent,
A cosmetic comprising one or more selected from the group consisting of an anti-dandruff agent and an anti-seborrheic agent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63199783A JP2681665B2 (en) | 1988-08-12 | 1988-08-12 | Cosmetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63199783A JP2681665B2 (en) | 1988-08-12 | 1988-08-12 | Cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0249712A true JPH0249712A (en) | 1990-02-20 |
JP2681665B2 JP2681665B2 (en) | 1997-11-26 |
Family
ID=16413538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63199783A Expired - Fee Related JP2681665B2 (en) | 1988-08-12 | 1988-08-12 | Cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2681665B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0717846A (en) * | 1993-06-30 | 1995-01-20 | Sansho Seiyaku Co Ltd | Skin external preparation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5449335A (en) * | 1977-09-14 | 1979-04-18 | Hoffmann La Roche | Cosmetic preparation |
JPS56159295A (en) * | 1980-02-07 | 1981-12-08 | Procter & Gamble | Shampoo composition |
-
1988
- 1988-08-12 JP JP63199783A patent/JP2681665B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5449335A (en) * | 1977-09-14 | 1979-04-18 | Hoffmann La Roche | Cosmetic preparation |
JPS56159295A (en) * | 1980-02-07 | 1981-12-08 | Procter & Gamble | Shampoo composition |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0717846A (en) * | 1993-06-30 | 1995-01-20 | Sansho Seiyaku Co Ltd | Skin external preparation |
Also Published As
Publication number | Publication date |
---|---|
JP2681665B2 (en) | 1997-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5073545A (en) | Agent containing an ellagic acid series compound for external application and use thereof | |
EP1002526B1 (en) | Skin whitening composition containing bearberry extract and a reducing agent | |
JP5093998B2 (en) | Pigmentation preventing or improving agent | |
AU670448B2 (en) | Cosmetic composition in the form of a water/oil/water triple emulsion with gelled external phase | |
JPH11501954A (en) | Use of octoxyglycerin as an active agent for treating seborrhea and / or acne in cosmetic and / or dermatological compositions | |
JP5766258B2 (en) | Pigmentation preventing or improving agent | |
JP4070065B2 (en) | Skin preparation for preventing and improving skin roughness | |
JP2002003373A (en) | Skin care preparation | |
DE69700111T2 (en) | Use of succinic anhydride derivatives in skin cleansing compositions | |
JPH0563451B2 (en) | ||
JPH05262635A (en) | Dermatic external preparation | |
JPH11139951A (en) | Cosmetic | |
DE102004012009A1 (en) | Antidandruff compositions, e.g. shampoos, containing synergistic active agent combination of acetylsalicylic acid, zinc pyrithione and piroctone olamine | |
JP2602069B2 (en) | Cosmetics | |
WO1989002731A1 (en) | Hair tonic | |
JPH0624954A (en) | Cosmetic | |
JPH10212225A (en) | Wrinkle preventive | |
JPH0249712A (en) | Cosmetic | |
JPH07138125A (en) | Dermal agent for external use | |
JPH10279427A (en) | Moisture-retaining cosmetic material composition | |
JPH08157337A (en) | Hair cosmetic | |
JPH0249714A (en) | Cosmetic | |
DE10240863A1 (en) | Use of 2- (4-diethylamino-2-hydroxybenzoyl) benzoic acid n-hexyl ester in cosmetic or dermatological preparations for the treatment of hair | |
DE19631220C2 (en) | Foamy or foamable preparations containing surfactants and electrolytes | |
JPS61238715A (en) | Hair cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |